Skip to main content


Page 13 of 13

  1. Today, scientists are often encouraged to custom-design vaccines based on a particular country or clade. Here, we review the scientific literature and then suggest that the overwhelming endeavor to produce a u...

    Authors: Karen S Slobod, Chris Coleclough, Scott A Brown, John Stambas, Xiaoyan Zhan, Sherri Surman, Bart G Jones, Amy Zirkel, Pamela J Freiden, Brita Brown, Robert Sealy, Mattia Bonsignori and Julia L Hurwitz

    Citation: AIDS Research and Therapy 2005 2:3

    Content type: Hypothesis

    Published on:

  2. Protease inhibitors (PIs) block HIV-1 maturation into an infectious virus particle by inhibiting the protease processing of gag and gag-pol precursor proteins. We have used a simple anti-HIV-1 p24 Western blot...

    Authors: Heather A Baird, Andre J Marozsan, Michael M Lederman, Alan Landay, Donna Mildvan, Daniel R Kuritzkes, Harold A Kessler and Eric J Arts

    Citation: AIDS Research and Therapy 2005 2:2

    Content type: Research

    Published on:

  3. RNA based antiviral approaches against HIV-1 are among the most promising for long-term gene therapy. These include ribozymes, aptamers (decoys), and small interfering RNAs (siRNAs). Lentiviral vectors are ide...

    Authors: Akhil Banerjea, Ming-Jie Li, Leila Remling, John Rossi and Ramesh Akkina

    Citation: AIDS Research and Therapy 2004 1:2

    Content type: Research

    Published on: